Lin, Chia-Chi

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 791

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 571

Phase I/Ib Clinical Trial of Sabatolimab, an Anti‐TIM‐3 Antibody, Alone and in Combination with Spartalizumab, an Anti‐PD‐1 Antibody, in Advanced Solid Tumors

Curigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, D., Forde, P. M., Sarantopoulos, J., Bedard, P. L., Lin, C.-C., Hodi, F. S., et al. (2021) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 362

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., et al. (2024) · Cancer Discovery

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 125

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

Takahashi, S., Karayama, M., Takahashi, M., Watanabe, J., Minami, H., Yamamoto, N., Kinoshita, I., Lin, C.-C., Im, Y.-H., Achiwa, I., et al. (2021) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchPharmacogenetics and Drug Metabolism

Cited by 37